» Articles » PMID: 29145741

A Cohort Approach to Real-Time Detection of Acute HIV Infections Among People Who Inject Drugs in St. Petersburg, Russia

Overview
Publisher Mary Ann Liebert
Date 2017 Nov 18
PMID 29145741
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

To detect acute HIV infections (AHIs) in real time among people who inject drugs (PWID) in St. Petersburg, Russia and to test the feasibility of this approach. Prospective cohort study. One hundred seronegative or acutely HIV-infected at screening PWID were enrolled and followed until the end of the 12-month pilot period. Each participant was evaluated, tested, and counseled for HIV monthly. Two HIV tests were used: HIV antibody and HIV RNA PCR. If diagnosed with AHI, participants were followed weekly for a month; then, monthly for 3 months; and then, quarterly for the duration of the follow-up period. HIV risk behavior was assessed at each study visit. Most enrolled PWID were 30-39 years old, male, completed high school or more, not employed full-time, heroin users, and frequently shared injection paraphernalia. AHI prevalence at screening was 1.8% [95% confidence interval (CI): 0.4, 5.5]. Three participants with AHI at enrollment represented 3% (95% CI: 0.6, 8.5) of the 100 participants who consented to enroll. Among the HIV-uninfected participants (n = 97), the AHI incidence over time was 9.3 per 100 person-years. Persons with AHI were more likely to report alcohol intoxication within the prior 30 days. This was the first study to detect AHI using a cohort approach. The approach proved to be feasible: recruitment, retention, AHI detection, and virological endpoints were successfully reached. A cost analysis in a real-world setting would be required to determine if this strategy could be brought to scale. The study revealed continued high HIV incidence rate among PWID in St. Petersburg, Russia and the importance of prevention and treatment programs for this group.

Citing Articles

Estimation of the Seroconversion Duration of HIV-1 Antibodies in Individuals With Recent Infection in China.

Kong W, Liu P, Tang L, Zhu Z, Xiao P, Zhan J Front Microbiol. 2019; 10:1322.

PMID: 31249564 PMC: 6582625. DOI: 10.3389/fmicb.2019.01322.


Characterization of the Transmitted Virus in an Ongoing HIV-1 Epidemic Driven by Injecting Drug Use.

Dukhovlinova E, Masharsky A, Vasileva A, Porrello A, Zhou S, Toussova O AIDS Res Hum Retroviruses. 2018; 34(10):867-878.

PMID: 29756455 PMC: 6204568. DOI: 10.1089/AID.2017.0313.

References
1.
Zhang Y, Shan H, Trizzino J, Ruan Y, Beauchamp G, Masse B . HIV incidence, retention rate, and baseline predictors of HIV incidence and retention in a prospective cohort study of injection drug users in Xinjiang, China. Int J Infect Dis. 2007; 11(4):318-23. DOI: 10.1016/j.ijid.2006.09.001. View

2.
Shaboltas A, Toussova O, Hoffman I, Heimer R, Verevochkin S, Ryder R . HIV prevalence, sociodemographic, and behavioral correlates and recruitment methods among injection drug users in St. Petersburg, Russia. J Acquir Immune Defic Syndr. 2006; 41(5):657-63. DOI: 10.1097/01.qai.0000220166.56866.22. View

3.
Ruan Y, Qin G, Yin L, Chen K, Qian H, Hao C . Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS. 2008; 21 Suppl 8:S39-46. DOI: 10.1097/01.aids.0000304695.54884.4f. View

4.
Degenhardt L, Mathers B, Wirtz A, Wolfe D, Kamarulzaman A, Carrieri M . What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. Int J Drug Policy. 2013; 25(1):53-60. DOI: 10.1016/j.drugpo.2013.08.004. View

5.
Mehta S, Galai N, Astemborski J, Celentano D, Strathdee S, Vlahov D . HIV incidence among injection drug users in Baltimore, Maryland (1988-2004). J Acquir Immune Defic Syndr. 2006; 43(3):368-72. DOI: 10.1097/01.qai.0000243050.27580.1a. View